

May 25, 2026

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Notice of partial amendment to the Articles of Incorporation

We would like to announce that our Board of Directors meeting held on May 25, 2026 has resolved to submit a proposal to amend the Articles of Incorporation as detailed below at the 27th Ordinary General Meeting of Shareholders to be held on June 25, 2026.

1. Purpose of the Amendment to the Articles of Incorporation

The Company has engaged in the research and development of pharmaceuticals and other products primarily targeting cancer and pulmonary diseases in Japan. In addition, the Company has recently been advancing research and development activities in the fields of anti-aging and longevity and is also focusing on healthcare-related businesses in these fields, where significant business potential is expected. In preparation for future business expansion, the Company proposes to partially amend the Articles of Incorporation in order to add the operation of medical institutions, entrusted services related to the operation of medical institutions, other healthcare-related businesses, and consulting services related thereto to the Company's business purposes.

2. Details of the Amendments to the Articles of Incorporation

The details of the amendments are as follows:

(Underlined parts indicate the changes.)

Current Articles of Incorporation	Proposed change
Chapter 1 General Provisions Article 1 (Articles omitted) (The purpose) Article 2 The purpose of the Company is to engage in the following businesses: 1. Research, development, manufacturing, import/export, marketing and sales of pharmaceuticals, medical devices, medical solutions utilizing artificial intelligence (AI), diagnostic agents and quasi-drugs	Chapter 1 General Provisions Article 1 (Same as present) (The purpose) Article 2 The purpose of the Company is to engage in the following businesses: 1. Research, development, manufacturing, import/export, marketing and sales of pharmaceuticals, medical devices, medical solutions utilizing artificial intelligence (AI), diagnostic agents and quasi-drugs

Current Articles of Incorporation	Proposed change
<p>2. Purchase, sale, licensing and management of industrial property rights, such as patent rights and trademark rights, and other intangible property rights and know-how in the medical and healthcare fields</p> <p>3. Consulting services related to pharmaceuticals, medical devices, medical solutions utilizing artificial intelligence (AI), diagnostic agents and quasi-drugs</p> <p>(Newly added)</p> <p><u>4.</u> All businesses related to the above</p> <p>Articles 3 to 37 (Articles omitted)</p>	<p>2. Purchase, sale, licensing and management of industrial property rights, such as patent rights and trademark rights, and other intangible property rights and know-how in the medical and healthcare fields</p> <p>3. Consulting services related to pharmaceuticals, medical devices, medical solutions utilizing artificial intelligence (AI), diagnostic agents and quasi-drugs</p> <p><u>4.</u> <u>Operation of medical institutions, entrusted services related to the operation of medical institutions, other healthcare-related businesses, and consulting services related thereto</u></p> <p><u>5.</u> All businesses related to the above</p> <p>Articles 3 to 37 (Same as present)</p>
<p>Supplementary provisions</p> <p>Article 1(Articles omitted)</p>	<p>Supplementary provisions</p> <p>Article 1 (Same as present)</p>

3. Schedule

The date of the general meeting of shareholders to amend the Articles of Incorporation:
June 25, 2026 (tentative)

Effective date of the amendment to the Articles of Incorporation: June 25, 2026 (tentative)